Similarly, axitinib, another TKI that also targets VEGF receptors, PDFR, and c-KIT, showed protective effects of reducing plaques and BBB leakage and improving memory performance in 10-month-old Tg2576 AD mice of both sexes [105]. Here, KIT is linked to Alzheimer disease.